HOOKIPA Pharma Inc. (HOOK)
OTCMKTS
· Delayed Price · Currency is USD
0.8310
-0.0090 (-1.07%)
Aug 15, 2025, 1:55 PM EDT
HOOKIPA Pharma Revenue
HOOKIPA Pharma had revenue of $2.00M in the quarter ending March 31, 2025, a decrease of -94.52%. This brings the company's revenue in the last twelve months to $9.35M, down -82.54% year-over-year. In the year 2024, HOOKIPA Pharma had annual revenue of $43.95M with 118.32% growth.
Revenue (ttm)
9.35M
Revenue Growth
-82.54%
P/S Ratio
1.13
Revenue / Employee
110.01K
Employees
87
Market Cap
10.55M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 206.83M |
Elite Pharmaceuticals | 84.04M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
BioStem Technologies | 332.45M |
HOOKIPA Pharma News
- 4 weeks ago - HOOKIPA Pharma to delist from Nasdaq and liquidate following Gilead asset sale - Seeking Alpha
- 4 weeks ago - HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock - GlobeNewsWire
- 6 months ago - HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”) - GlobeNewsWire
- 7 months ago - Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA - GlobeNewsWire
- 7 months ago - HOOKIPA Pharma Inc - FORM 8 (OPD) - GlobeNewsWire
- 7 months ago - HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements - GlobeNewsWire
- 7 months ago - HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment - GlobeNewsWire
- 8 months ago - Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc. - GlobeNewsWire